Literature DB >> 9861197

In-vitro metabolism of anti-cancer drugs, methods and applications: paclitaxel, docetaxel, tamoxifen and ifosfamide.

K M Crommentuyn1, J H Schellens, J D van den Berg, J H Beijnen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9861197     DOI： 10.1016/s0305-7372(98)90057-3

Source DB:  PubMed          Journal:  Cancer Treat Rev        ISSN： 0305-7372            Impact factor:   12.111


× No keyword cloud information.
  6 in total

Review 1.  Clinical pharmacokinetics and pharmacodynamics of ifosfamide and its metabolites.

Authors:  T Kerbusch; J de Kraker; H J Keizer; J W van Putten; H J Groen; R L Jansen; J H Schellens; J H Beijnen
Journal:  Clin Pharmacokinet       Date:  2001-01       Impact factor: 6.447

Review 2.  Drug interactions of paclitaxel and docetaxel and their relevance for the design of combination therapy.

Authors:  L Vigano; A Locatelli; G Grasselli; L Gianni
Journal:  Invest New Drugs       Date:  2001-05       Impact factor: 3.850

3.  Whole flaxseed diet alters estrogen metabolism to promote 2-methoxtestradiol-induced apoptosis in hen ovarian cancer.

Authors:  Anushka Dikshit; Karen Hales; Dale Buchanan Hales
Journal:  J Nutr Biochem       Date:  2017-01-23       Impact factor: 6.048

Review 4.  Role of Genetic Polymorphisms in Drug-Metabolizing Enzyme-Mediated Toxicity and Pharmacokinetic Resistance to Anti-Cancer Agents: A Review on the Pharmacogenomics Aspect.

Authors:  Gera Narendra; Shalki Choudhary; Baddipadige Raju; Himanshu Verma; Om Silakari
Journal:  Clin Pharmacokinet       Date:  2022-09-30       Impact factor: 5.577

5.  Phase I study of axitinib combined with paclitaxel, docetaxel or capecitabine in patients with advanced solid tumours.

Authors:  L P Martin; M F Kozloff; R S Herbst; T A Samuel; S Kim; B Rosbrook; M Tortorici; Y Chen; J Tarazi; A J Olszanski; T Rado; A Starr; R B Cohen
Journal:  Br J Cancer       Date:  2012-09-20       Impact factor: 7.640

Review 6.  Regulation of multidrug resistance by microRNAs in anti-cancer therapy.

Authors:  Xin An; Cesar Sarmiento; Tao Tan; Hua Zhu
Journal:  Acta Pharm Sin B       Date:  2016-12-03       Impact factor: 11.413
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.